Hepatitis B: Clinical application of HBsAg quantification;Hépatite B: Intérêt clinique de la quantification de l'AgHBs

Annales de Biologie Clinique

Volumn 71, Issue SPEC. ISSUE 1, 2013, Pages 19-26

  Martinot Peignoux, Michelle ^a   Marcellin, Patrick ^a   Asselah, Tarik ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Analogues; HBV tools; PEG IFN; Personalized medicine; Prediction; Prognosis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ANALOGUES; ARTICLE; DISEASE COURSE; HBV TOOLS; HEPATITIS B; HUMAN; IMMUNOLOGY; LIVER; METHODOLOGY; PATHOLOGY; PEG-IFN; PERSONALIZED MEDICINE; PHYSIOLOGIC MONITORING; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; SEROLOGY; VIROLOGY;

ANALOGUES; HBV TOOLS; PEG-IFN; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS;

DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SEROLOGIC TESTS; VIROLOGY;

EID: 84890356218     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2013.0898     Document Type: Article

References (43)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 118-29.
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-55.
3. Werle-Lapostolle B., Bowden S, Locarnini S., Wursthorn K, Petersen J, Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
4. Madalinski K, Burczynska B, Heermann KH. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991; 84: 493-500.
5. Chan HL, Wong VW, Tse A.M., Tse CH, Chim AHL, Chan HL, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8.
6. Nguyen T, Thompson AJ, Bowden S, Croagh C., Bel S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
7. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K., Schlue S, Raupach R, et al. Hepatitis B surface antigen [HBsAg] levelsin the natural history of hepatitis B virus [HBV]-infection: a European perspective. J Hepatol 2010; 52: 514-22.
8. Blumberg BS, Gerstley BJ, Hungerford D.A., London WT, Sutnick AI. A serum antigen [Australia antigen] in Down's symdrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-31.
9. Jia JD, Hong M, Wei L., Zhang XX, Mao YL, Wang LL, et al. Mul-ticentre evaluation of Elecsys hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assyas. Med Microbiol Immunol 2009; 198: 263-9.
10. Liaw YF. Clinical utility of hepatitis B surface antigen quantification in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-9.
11. Chan HL, Wong GL, Wong VW. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489-99.
12. Martinot-Peignoux M., Lapalus M, Asselah T., Marcellin P. The role of HBsAg quantification for monitoring natural histoty and treatment outcome. Liver International 2013; 33: 125-32.
13. Lui J, Yang HI, Lee M.H., Lu Sh. MH, Jen CL, Wang Ly CL, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2012; 139: 474-82.
14. Lui J, Lee MH, Batrla-Utermann R, Jen C.L., Iloeje UH, Lu SN, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013; 58: 845-60.
15. Martinot-Peignoux M., Lapalus M, Laouénan C, Lada O., Ana Carolina Ferreira Netto-Cardoso O, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013; 58: 401-7.
16. EASL clinical practice guidelines: management of chronic hepatitis B. European Association for the study of the liver. J Hepatol 2012; 50: 227-42.
17. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
18. Seto WK, Wnog DKH, Fung J, Ip PPC, Yuen JCH, Hing IFN, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLOS one 2012; 7: e43087.
19. Martinot-Peignoux M., Carvalho RJ, Lapalus M, Cardoso A.C., Lada O., Bartla R, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e-antigen-positive patients. J Hepatol 2013; 58: 1089-95.
20. Tseng TC, Liu CJ, Yang H.C., SU TH, Wang CC, Chen Cl, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HCV load. Gastroenterology 2012; 142: 1140-9.
21. Chang TT, Liaw YF, Wu S.S., Schiff E., Han KH, Lai CL, et al. Long term entecavir therapy results in the reversal of fibrosis/cirhosis and continued histological improvementin patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
22. Marcellin P, Gane E, Buti M., Afdal N, Sievert W, Jacobson I.M., et al. Regression of fibrosis during treatment with tenefovir disoproxil fumarate for chronic hepatitis B: a five years open label follow-up study. The Lancet 2013; 381: 9-15.
23. Chan HL, Thompson A, Martinot-Peignoux Piratvisuth T, Cornberg M, Brunetto M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - A core group report. J Hepatol 2011; 55: 1121-31.
24. Chan HL, Wong VW, Chim A.M., Chan GLH, Wong J, Sang JY. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-31.
25. Tangkijvanich P, Komolmit P, Mahachai V., Sanguanmoo P, Theamboonler A., Poovorawany Y, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to peginterferon alfa-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-23.
26. Lau G, Marcellin P, Brunetto M. On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50: S333.
27. Gane E, Jia J, Han K., Tanwandee T, Chuang WL, Marcellin P, et al. NEPTUNE study; on treatment HBs Ag level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg positive patients. J Hepatol 2011; 54: abst 69.
28. Sonneveld MJ, Rijckborst V, Boucher C.A., Hansen BE, Janssen HLA. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
29. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients. Hepatology 2011; 53: 1054-5.
30. Sonneveld MJ, Hansen BE, Piratvisuth T, jia J.D., Zeuzem S., Gane E, et al. Response guide peginterferon therapy in HBeAg-postive chronic hepatitis B using hepatitis B surface antigen levels. Hepatology 2013; 58: 872-80.
31. Marcellin P, Lau GKK, Bonino F, Farci P., Hadzianinis S, Jin R, et al. Peginterferon alfa-2a, lamuvidine, and the two in combination for HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
32. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P., Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
33. Marcellin P, Bonino F, Lau G.K., Farci P., Yurdayin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
34. Moucari R, Mackiewicz V, Lada O., Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
35. Brunetto MR, Moriconi F, Bononi F., Lau GKK, Farci P, Yurdayin C., et al. Hepatitis B virus surface antigen levels: a guide to sutained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
36. Reijnders JG, Rijckborst V, Sonneveld M.J., Scherbeijn SMJ, boucher SMJ, Hansen B, et al. Kinetics of hepatits B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
37. Lee MH, Lee DM, Kim S.S., Cheong JY, Cho SW. Correlation of serum hepatitis B srface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011; 83: 1178-86.
38. Lee JM, Ahn SH, Kim H.S., Park H., Chang HY, Kim DY, et al. Quantitative hepatitis B surface antigen and hepatitis B e atigen titers in prediction of treatment response to entecavir. Hepatology 2010; 53: 1486-93.
39. Zoulim F, Carosi G, Greenbloom S., Marzur W, Nguyen T, Jeffers L., et al. Quantification of HBsAg in nucleos[t]ides-naive patients treated for chronic hepatitis B with entecavir or entecavir plus tenofovir in the BE-LOW study. J Viral hepatitis 2012; 19: O224.
40. Marcellin M, Heathcote EJ, Buti M, Gane E., de Man RA, Krastev Z, et al. Tenofovir disiproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
41. Heathcote EJ, Marcellin M, Buti M., Gane E, de Man RA, Krastev Z, et al. Three years efficacy and safety of tenofovir disiproxil fumarate treatment for chronic hepatitis B. Gastroenterrology 2011; 140: 132-43.
42. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chen RN, Liu C.J., et al. Asian-Pacific consensus statementon the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 561-92.
43. Liang Y, Jiang J, Su M., Liu Z, Guo W, Huang X., et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.